| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_963f454f35852505e2092f858fef61a2 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 |
| filingDate |
1993-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1996-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68a3aa3cccb2d73c0355bc4c9edca3e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68fcca79fefb97cb83871325d74f5a02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c84f67a58bfc1b85f9a055fe313034d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f3d84ab54fd9fe9db8f538a4fe1eac8 |
| publicationDate |
1996-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2062096-C1 |
| titleOfInvention |
Agent for immunodeficiency state treatment |
| abstract |
FIELD: medicine, pharmacology. SUBSTANCE: hexapeptide is proposed as an agent for treatment of immunodeficiency states of the following structure: arginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine. EFFECT: enhanced effectiveness of agent. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2550966-C1 |
| priorityDate |
1993-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |